The efficacy of secondary cytoreductive surgery for recurrent ovarian tubal or peritoneal cancer in Tian-model low-risk patients

摘要

ObjectiveIn patients with recurrent ovarian cancer (ROC) in whom surgery is likely to render them disease-free, it is unclear whether secondary cytoreductive surgery (SCS) combined with chemotherapy is superior to chemotherapy alone. The aim of this study was to evaluate the 2 treatment options in Tian-model low-risk patients.